Posted by Michael Wonder on 24 Aug 2020
CADTH publishes final recommendation on new indication for Soliris
24 August 2020 - The new indication is for the treatment of patients with neuromyelitis optica spectrum disorder.
The CADTH Canadian Drug Expert Committee has recommended that eculizumab be reimbursed for the treatment of NMOSD in adult patients who are anti-aquaporin-4 antibody positive only if certain conditions are met.
The conditions of course include a reduction in price; "a price reduction on eculizumab of 96% would be required to achieve an ICER below a willingness-to-pay threshold of $50,000 per QALY."
